Pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL; murine models of erythroid 5ALA synthesis disorders; targeting PKCa in diabetes and hemochromatosis
This episode covers the safety and efficacy of pirtobrutinib with venetoclax in relapsed/refractory CLL, discusses murine models of erythroid 5ALA synthesis disorders, and explores how targeting PKC alpha can alleviate iron overload.